Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.98 USD
Change Today +0.04 / 0.81%
Volume 28.2K
SVA On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

sinovac biotech ltd (SVA) Snapshot

Open
$4.92
Previous Close
$4.94
Day High
$5.01
Day Low
$4.89
52 Week High
05/13/14 - $6.53
52 Week Low
09/30/14 - $4.51
Market Cap
274.4M
Average Volume 10 Days
70.7K
EPS TTM
$-0.02
Shares Outstanding
55.1M
EX-Date
--
P/E TM
82.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for SINOVAC BIOTECH LTD (SVA)

sinovac biotech ltd (SVA) Related Businessweek News

No Related Businessweek News Found

sinovac biotech ltd (SVA) Details

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against hepatitis A, hepatitis B, influenza viruses, and mumps in the People's Republic of China. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; Split viron pandemic influenza vaccine; and RabEnd, an animal rabies vaccine. The company also develops the EV71 vaccine, which has completed Phase III clinical trial. In addition, it has completed pre-clinical studies for varicella, sabin inactivated polio, and hepatitis A and B vaccines; and focuses on commencing clinical trials for pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, and rubella vaccine. The company has a collaboration agreement with Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

sinovac biotech ltd (SVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sinovac biotech ltd (SVA) Key Developments

Sinovac Biotech Ltd. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Sinovac Biotech Ltd. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Quarterly sales were $20.3 million, a decrease of 11.4% from $22.9 million in the prior year period. Excluding revenue recognized from the stockpiling of H5N1 pandemic influenza vaccine of $0.1 million in the fourth quarter of 2014 and $7.2 million in the fourth quarter of 2013, the Company's fourth quarter 2014 regular product sales were $20.2 million, an increase of 28.2% from $15.8 million in the prior year period. Net income attributable to common stockholders was $1.3 million, or $0.02 per basic and diluted share for the fourth quarter of 2014, compared to $5.8 million, or $0.10 per basic and diluted share, for the fourth quarter of 2013. Operating income was $1.932 million against $5.805 million a year ago. Income before income taxes and non-controlling interests were $2.754 million against $5.663 million a year ago. Net cash provided by operating activities was $7.501 million against $19.916 million a year ago. Acquisition of property, plant and equipment was $3.696 million against $1.739 million a year ago. For the year, total sales were $63.1 million, a decrease of 13.0% from $72.5 million in the prior year. Excluding revenue recognized from the stockpiling of H5N1 pandemic influenza vaccine of $0.2 million in 2014 and $10.7 million in 2013, the Company's annual sales of regular products were $62.9 million, an increase of 1.8% from $61.8 million in the prior year. Net loss attributable to common stockholders was $0.9 million, or $0.02 per basic and diluted share in 2014, compared to a net income attributable to common shareholders of $7.4 million, or $0.13 per basic and diluted share in 2013. Operating income was $0.488 million against $8.745 million a year ago. Income before income taxes and non-controlling interests were $1.122 million against $8.145 million a year ago. Net cash used in operating activities was $8.647 million against net cash provided by operating activities of $5.576 million a year ago. Acquisition of property, plant and equipment was $11.003 million against $5.176 million a year ago.

Sinovac Biotech Ltd. to Report Q4, 2014 Results on Apr 20, 2015

Sinovac Biotech Ltd. announced that they will report Q4, 2014 results at 9:00 AM, China Standard Time on Apr 20, 2015

Sinovac Biotech Ltd. Provides Updates on Pipeline Vaccines

Sinovac Biotech Ltd. provided updates on the Company's pipeline vaccines. EV71 vaccine. The Company submitted supplementary documentation to the China Food and Drug Administration (CFDA) at the end of January 2015, as required following review of the new drug application (NDA) by an expert panel in November 2014. The CFDA has begun its review of the supplementary documentation. Sinovac maintains regular communication with relevant departments of CFDA, in order to be prepared for the upcoming on-site inspection, sample testing, and production and lot release after the product is commercialized. Once the on-site inspection and sample testing are successfully completed, Sinovac will receive the new drug certificate, production license and GMP license to begin commercial production of its EV71 vaccine. EV71 is a virus that causes hand, foot and mouth disease (HFMD) and is the primary cause of most severe and fatal cases of hand, foot and mouth disease (HFMD) in China. According to the Chinese CDC, there were approximately 2.78 million reported cases of HFMD in 2014 and 508 fatal cases. Pneumococcal 23-valent polysaccharide vaccine (PPV). The Company obtained its clinical trial license in May 2014. Sinovac is currently completing clinical trial preparations and expects to start trials in the first half of 2015. Varicella vaccine. The Company is currently preparing supplementary material for the clinical trial application, following review by an expert panel in November 2014. The Company expects to receive its clinical trial license in 2015. Sinovac filed the clinical trial application with the CFDA in January 2013. Pneumococcal 13-valent conjugate vaccine (PCV). The Company obtained its clinical trial license in January 2015, having filed its application with the CFDA in March 2011. PCV is targeted for children under two years old. Sinovac will finalize its clinical trial protocols based on Good Clinical Practice (GCP) and related technical guidelines and initiate production and testing for vaccines to be used in clinical trial accordingly. The Company is required to commence the trials within three years after the license is issued. Sabin-inactivated polio vaccine (sIPV). The clinical trial application for the vaccine was accepted by Beijing Food and Drug Administration in October 2014 and is under review by the CDE. Hepatitis B vaccine and new generation of hepatitis A & B vaccine. The Company has completed pre-clinical studies for its proprietary hepatitis B vaccine and filed a clinical trial application in December 2014. Simultaneously, Sinovac is developing a new generation of its hepatitis A & B combination vaccine based on its individual hepatitis A and B vaccines. The new generation combination vaccine will contain a higher dosage of the hepatitis B component, 10ug and 20ug for pediatric and adult formulations, respectively, to enhance the vaccine's immunogenicity. And the clinical trial application for the combined vaccine was submitted in December 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVA:US $4.98 USD +0.04

SVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,512 GBp -3.00
Hualan Biological Engineering Inc CNY53.80 CNY +0.63
View Industry Companies
 

Industry Analysis

SVA

Industry Average

Valuation SVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SINOVAC BIOTECH LTD, please visit www.sinovac.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.